A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(6 sites)

China

Peking University Cancer Hospital, Beijing, Beijing Municipality

Fujian Provincial Cancer Hospital, Fuzhou, Fujian

Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality

Tianjin Provincial Tumor Hospital, Tianjin, Tianjin Municipality